FDA.reportPublic FDA data

tofacitinib 10 MG Oral Tablet

RxCUI
2048566
RxNorm name
tofacitinib 10 MG Oral Tablet
Display name
tofacitinib 10 MG Oral Tablet
Full name
tofacitinib 10 MG Oral Tablet
Term type
SCD
Status
DailyMed mapping
Updated
2026-06-04 23:39:22

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 10 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
TOFACITINIBTOFACITINIBMicro Labs Limitedffa6819b-23a4-478b-8fb7-cc90e8142fc52026-07-31Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
tofacitinibTOFACITINIBZydus Pharmaceuticals USA Inc.21a89264-8047-40ac-8b10-fa64610725092026-07-30Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
TofacitinibTOFACITINIBAvKARE5751321a-c904-44ae-e063-6394a90a26542026-07-23Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
TOFACITINIBTOFACITINIBAurobindo Pharma Limited50962b08-99dd-ae73-e063-6394a90ad1eb2026-07-17Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
XELJANZTOFACITINIBU.S. Pharmaceuticals68e3d6b2-7838-4d2d-a417-09d919b43e132026-07-13Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
XELJANZ XRTOFACITINIBPfizer Laboratories Div Pfizer Inccf74ba2f-afc5-4baa-8594-979c889a58312026-07-12Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
TofacitinibTOFACITINIBNovadoz Pharmaceuticals LLC253635c8-1ea7-41ba-b216-dea5e3305c472026-06-06Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
TOFACITINIBTOFACITINIBSomerset Therapeutics, LLC2726c2b0-c763-4635-ac6b-4334c3a5a8bc2026-06-02Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566
tofacitinibTOFACITINIBZydus Lifesciences Limitedf4d0e580-74a8-496e-89a2-d74478c946bf2026-05-29Exact identifier
rxcui: 2048566
TofacitinibTOFACITINIB CITRATEBreckenridge Pharmaceutical, Inc.c963c610-52e5-43ab-aac6-3f7e5341b7642026-05-07Boxed warning, Warnings, Adverse reactionsExact identifier
rxcui: 2048566

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
cf74ba2f-afc5-4baa-8594-979c889a5831tofacitinib 10 MG Oral TabletSCD53These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260312
cf74ba2f-afc5-4baa-8594-979c889a5831tofacitinib 10 MG (as tofacitinib citrate 16 MG) Oral TabletSY53These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260312
cf74ba2f-afc5-4baa-8594-979c889a5831tofacitinib 10 MG Oral TabletPSN53These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260312
68e3d6b2-7838-4d2d-a417-09d919b43e13tofacitinib 10 MG (as tofacitinib citrate 16 MG) Oral TabletSY17These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260327
68e3d6b2-7838-4d2d-a417-09d919b43e13tofacitinib 10 MG Oral TabletPSN17These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260327
68e3d6b2-7838-4d2d-a417-09d919b43e13tofacitinib 10 MG Oral TabletSCD17These highlights do not include all the information needed to use XELJANZ/XELJANZ XR safely and effectively. See full prescribing information for XELJANZ/XELJANZ XR. XELJANZ ® (tofacitinib) tablets, for oral use XELJANZ ® (tofacitinib) oral solution XELJANZ ® XR (tofacitinib) extended-release tablets, for oral use Initial U.S. Approval: 201220260327